Kairos Pharma, Ltd. Common Stock
Key Metrics
Market Snapshot
About
Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical company based in Los Angeles, California, focused on developing novel treatments for cancer. The company is best known for its work in immunotherapy and cell therapy, advancing a pipeline of drug candidates targeting various solid tumors.
The company generates revenue through strategic partnerships and grants while advancing its therapeutic candidates through clinical trials. Its primary approach involves developing treatments designed to harness or modulate the body's immune system to fight cancer. These include antibody-based therapies and small-molecule drugs. The company's most advanced candidate is ENV 105, an antibody therapeutic currently in a Phase 2 clinical trial for prostate cancer and a Phase 1 trial for non-small cell lung cancer.
Kairos Pharma's preclinical pipeline includes several other promising programs. These include KROS 201, a cell therapy for glioblastoma, and a series of small molecules like KROS 101 and KROS 102, designed to modulate specific immune pathways for cancer and autoimmune diseases. The company also has candidates targeting specific biomarkers in cancers such as triple-negative breast cancer, including KROS 301 and KROS 401. Kairos Pharma was incorporated in 2013 and was formerly known as NanoGB13, Inc. before changing its name in July 2016, reflecting its evolved focus on broader cancer immunotherapies.